Compare CTGO & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTGO | ARVN |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.3M | 516.2M |
| IPO Year | 2010 | 2018 |
| Metric | CTGO | ARVN |
|---|---|---|
| Price | $17.22 | $8.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 19 |
| Target Price | ★ $41.00 | $15.05 |
| AVG Volume (30 Days) | ★ 775.0K | 760.4K |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 19.77 | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.50 | $6.06 |
| 52 Week High | $34.38 | $14.22 |
| Indicator | CTGO | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 53.38 |
| Support Level | $16.37 | N/A |
| Resistance Level | $18.50 | $10.18 |
| Average True Range (ATR) | 0.91 | 0.42 |
| MACD | 0.36 | 0.16 |
| Stochastic Oscillator | 67.50 | 77.70 |
Contango Silver & Gold Inc, formerly Contango Ore Inc operates in the United States. The company is engaged in the exploration for and development of gold ore and associated minerals in the State of Alaska. The company's focus is the exploration of a mineral lease with the Native Village of Tetlin, whose governmental entity is the Tetlin Tribal Council, for the exploration of minerals near Tok, Alaska. It has formed a joint venture to advance exploration of the Tetlin Property, which is prospective for gold and associated minerals. The Peak Gold JV Property is located in the Tetlin Hills and Mentasta Mountains of eastern interior Alaska. Its exploration projects are Lucky Shot, Johnson Tract, Eagle, Hona, Shamrock, and Triple Z.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.